Cargando…

Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma

Neovascularization, an essential event for the growth of solid tumors, is regulated by a number of angiogenic factors. One such factor, vascular endothelial growth factor (VEGF), is considered to exert a potent angiogenic activity, as indicated by immunohistochemical and molecular evidence. In this...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Kazunari, Tsuchiya, Norihiko, Sasaki, Ryusei, Shimoda, Naotake, Satoh, Shigeru, Ogawa, Osamu, Kato, Tetsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926146/
https://www.ncbi.nlm.nih.gov/pubmed/10543260
http://dx.doi.org/10.1111/j.1349-7006.1999.tb00829.x
_version_ 1783318847941509120
author Sato, Kazunari
Tsuchiya, Norihiko
Sasaki, Ryusei
Shimoda, Naotake
Satoh, Shigeru
Ogawa, Osamu
Kato, Tetsuro
author_facet Sato, Kazunari
Tsuchiya, Norihiko
Sasaki, Ryusei
Shimoda, Naotake
Satoh, Shigeru
Ogawa, Osamu
Kato, Tetsuro
author_sort Sato, Kazunari
collection PubMed
description Neovascularization, an essential event for the growth of solid tumors, is regulated by a number of angiogenic factors. One such factor, vascular endothelial growth factor (VEGF), is considered to exert a potent angiogenic activity, as indicated by immunohistochemical and molecular evidence. In this study we investigated the serum VEGF level (s‐VEGF) in patients with renal cell carcinoma (RCC). s‐VEGF in peripheral blood samples was analyzed in 40 RCC patients and 40 patients without cancer (controls) using a sandwich enzyme‐linked immunoassay. In 20 RCC patients, serum samples were obtained separately from the bilateral renal veins. s‐VEGF was also measured before, 4 and 8 weeks after nephrectomy in 11 patients. There were significant differences in s‐VEGF between the RCC patients and the controls (207.3 ± 32.9 vs. 71.5 ± 9.1 pg/ml, mean ± SE) (P < 0.005), between the tumor‐bearing renal veins and the contralateral ones (P < 0.01), between the pre‐ and post‐nephrectomy situations (P < 0.01) and among the various parameters of tumor status such as tumor extent (P < 0.001) and existence of metastasis (P < 0.001). s‐VEGF significantly correlated with the tumor volume obtained by a three‐dimensional measurement (r= 0.802, P < 0.0001). The sensitivity and specificity of s‐VEGF at the cut‐off level of 100 pg/ml, as determined by the receiver‐operating‐characteristics curve, were 80.0% and 72.5%, respectively. The results indicate that tumor tissue of RCC liberates VEGF into the systemic blood flow and that s‐VEGF is a possible marker for RCC.
format Online
Article
Text
id pubmed-5926146
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-59261462018-05-11 Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma Sato, Kazunari Tsuchiya, Norihiko Sasaki, Ryusei Shimoda, Naotake Satoh, Shigeru Ogawa, Osamu Kato, Tetsuro Jpn J Cancer Res Article Neovascularization, an essential event for the growth of solid tumors, is regulated by a number of angiogenic factors. One such factor, vascular endothelial growth factor (VEGF), is considered to exert a potent angiogenic activity, as indicated by immunohistochemical and molecular evidence. In this study we investigated the serum VEGF level (s‐VEGF) in patients with renal cell carcinoma (RCC). s‐VEGF in peripheral blood samples was analyzed in 40 RCC patients and 40 patients without cancer (controls) using a sandwich enzyme‐linked immunoassay. In 20 RCC patients, serum samples were obtained separately from the bilateral renal veins. s‐VEGF was also measured before, 4 and 8 weeks after nephrectomy in 11 patients. There were significant differences in s‐VEGF between the RCC patients and the controls (207.3 ± 32.9 vs. 71.5 ± 9.1 pg/ml, mean ± SE) (P < 0.005), between the tumor‐bearing renal veins and the contralateral ones (P < 0.01), between the pre‐ and post‐nephrectomy situations (P < 0.01) and among the various parameters of tumor status such as tumor extent (P < 0.001) and existence of metastasis (P < 0.001). s‐VEGF significantly correlated with the tumor volume obtained by a three‐dimensional measurement (r= 0.802, P < 0.0001). The sensitivity and specificity of s‐VEGF at the cut‐off level of 100 pg/ml, as determined by the receiver‐operating‐characteristics curve, were 80.0% and 72.5%, respectively. The results indicate that tumor tissue of RCC liberates VEGF into the systemic blood flow and that s‐VEGF is a possible marker for RCC. Blackwell Publishing Ltd 1999-08 /pmc/articles/PMC5926146/ /pubmed/10543260 http://dx.doi.org/10.1111/j.1349-7006.1999.tb00829.x Text en
spellingShingle Article
Sato, Kazunari
Tsuchiya, Norihiko
Sasaki, Ryusei
Shimoda, Naotake
Satoh, Shigeru
Ogawa, Osamu
Kato, Tetsuro
Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma
title Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma
title_full Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma
title_fullStr Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma
title_full_unstemmed Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma
title_short Increased Serum Levels of Vascular Endothelial Growth Factor in Patients with Renal Cell Carcinoma
title_sort increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926146/
https://www.ncbi.nlm.nih.gov/pubmed/10543260
http://dx.doi.org/10.1111/j.1349-7006.1999.tb00829.x
work_keys_str_mv AT satokazunari increasedserumlevelsofvascularendothelialgrowthfactorinpatientswithrenalcellcarcinoma
AT tsuchiyanorihiko increasedserumlevelsofvascularendothelialgrowthfactorinpatientswithrenalcellcarcinoma
AT sasakiryusei increasedserumlevelsofvascularendothelialgrowthfactorinpatientswithrenalcellcarcinoma
AT shimodanaotake increasedserumlevelsofvascularendothelialgrowthfactorinpatientswithrenalcellcarcinoma
AT satohshigeru increasedserumlevelsofvascularendothelialgrowthfactorinpatientswithrenalcellcarcinoma
AT ogawaosamu increasedserumlevelsofvascularendothelialgrowthfactorinpatientswithrenalcellcarcinoma
AT katotetsuro increasedserumlevelsofvascularendothelialgrowthfactorinpatientswithrenalcellcarcinoma